Insulin glargine use and breast cancer risk: Associations with cumulative exposure

Paul J. H. L. PeetersUtrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands;

Marloes T. BazelierUtrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands;

Hubert G. M. LeufkensUtrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands;

Anssi AuvinenSchool of Health Sciences, University of Tampere, Tampere, Finland;

Tjeerd P. van StaaUtrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands; ;Health eResearch Centre, Farr Institute for Health Informatics Research, University of Manchester, Manchester, UK;

Frank de VriesUtrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands; ;Medical Center Maastricht and School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, The Netherlands; ;MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK; ;Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center, Maastricht, The Netherlands.

Marie L. De BruinUtrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands; Correspondence[email protected]

show all

Insulin glargine use and breast cancer risk: Associations with cumulative exposure

Articles from other publishers (11)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Insulin glargine use and breast cancer risk: Associations with cumulative exposure

Citations (11)

Articles from other publishers (11)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date